Good day, and thank you for standing by. Welcome to the Predictive Oncology Q3 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be an opportunity to ask your questions. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker for today, Mr. Glenn Garmont, Investor Relations. Mr. Garmont, please go ahead. Welcome, and thank you everyone for dialing into the Predictive Oncology third quarter 2023 earnings call. First, you'll hear from our Chief Executive Officer and Chairman of the Board, Raymond Vennare. Then our Chief Financial Officer, Josh Blacher, will review our financials. Finally, Dr. Pamela Bush, our Chief Business Officer, will join Raymond and Josh to answer any questions that you may have. Certain matters discussed on this call contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties, and assumptions about our operations and the investments we make. All statements other than statements of historical facts included in the call regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans, and objectives of management are forward-looking statements. The words anticipate, believe, estimate, expect, intend, may, plan, would, target, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors, including, among other things, factors discussed under the heading Risk Factors in our filings with the SEC. Except as expressly required by law, the company disclaims any intent or obligation to update these forward-looking statements. Now, I would like to turn the call over to Raymond Vennare, Chief Executive Officer. Raymond? Glenn, thank you very much, and, good morning, everyone. In March of this year, we were very pleased to announce a research collaboration with Cancer Research Horizons, whereby we would utilize our AI drug discovery platform, our PEDAL platform, to evaluate several CRH preclinical glutaminase inhibitor drug compounds to determine which cancer types and patient populations are most likely to respond to treatment with these compounds. As a reminder, CRH is the innovative engine at the core of Cancer Research UK, the largest independent funder of cancer research in the world. CRH has a network of more than 4,000 cancer researchers, an annual research spend of more than $370 million, 11 drugs currently on the market, and another 160 candidates in various stages of development. Today, I am pleased to announce that we have provided CRH with the initial results of this research collaboration, which, as you might imagine, is a very significant milestone for our company, not only in terms of the results themselves, but because we were able to achieve these results in a matter of weeks. By prioritizing the development of the strongest candidates for the ideal tumor types, based upon the output from PEDAL, CRH can save significant time and resources by pursuing only those projects that are most likely to succeed in the clinic. With our proprietary biobank of more than 150,000 tumor samples and CLIA-certified wet lab, we believe we can predict, with a higher degree of accuracy than anyone else, the probability of clinical success, because we are able to introduce patient and tumor heterogeneity into the very earliest stages of drug development. We can support our predictions with actual in silico modeling and bench-level experimentation. With our data in hand, CRH can now prioritize the development of these compounds and seek potential licensing deals with large pharmaceutical companies for further development. This is significant for two reasons. First, because we are now eligible for development and commercialization milestones in the event that a licensing deal is executed, as well as potential sales royalties. And second, because we believe the success of this first campaign, which, as I said, was completed in several weeks, should pave the way for additional projects from CRH. It is difficult to overstate the significance of the external validation that our initial campaign with CRH provides, and this relationship has had a very positive impact on our business development efforts elsewhere. I am pleased with our progress to date and believe we have created a solid foundation on which to drive future growth. The emergence of AI is fundamentally changing how drugs are discovered and subsequently developed, and we are at the forefront of this exciting and foundational transformation. It is well known and generally accepted that approximately 95% of drug candidates never receive commercial approval. But with our unique capabilities, our partners can gain insight into the future of heterogeneous drug response and confidently make strategic clinical drug development decisions with lower financial risk and greater likelihood of commercial success. Turning now to another significant development since our last quarterly update, we announced just last week that we have successfully completed a multi-year retrospective study with UPMC Magee-Womens Hospital in Pittsburgh. The purpose of this study was to build multi-omic machine learning models that could predict overall short and long-term survival in ovarian cancer. The study incorporated one of the largest sets of multi-omic data from 235 ovarian cancer patients, derived from tumor samples obtained at the time of diagnosis or first surgical intervention. The study was designed to identify the key features that drive overall survival endpoints, and in fact, we have been able to deliver strong predictive models with high levels of accuracy. These data will be presented at multiple national medical meetings in 2024, and we are considering future initiatives to both expand and further utilize these cohorts. The power of our technology is made obvious here, because our multi-omic machine learning models have the potential to identify and define certain prognostic subgroups within ovarian cancer. High-grade serous carcinomas, for example, of the ovary, make up most ovarian cancer cases and have the lowest survival rates. As far as next steps are concerned, there is certainly an opportunity to learn more about features that were identified as having prognostic importance for the model. This includes features that originate from our own digital pathology slide library. Ultimately, these models could support the tailoring of therapies to individual patients with the goal of positively affecting the overall survival of ovarian cancer patients and the development of invaluable clinical support tools. Clearly, there's an opportunity here to explore drug rescue or repurposing for the treatment of ovarian cancer, and in the process of discovery and development, identify significant intellectual property that is specific to these predictive models and beneficial to an AI-driven decision support platform. I would like to take a moment now to review some other significant projects that are ongoing. As you may recall, in February of this year, Predictive Oncology and Cvergenx announced a partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery utilizing artificial intelligence. The objective of this collaboration was to leverage and maximize the combined power of Predictive Oncology's expertise in artificial intelligence and Cvergenx's proficiency in biomarker development for radiation therapy to identify novel radioprotector and radiosensitizer drugs. Since then, we have evaluated, trained, or developed models to predict changes in radiosensitivity for more than 3,000 different drug exposures using well-established gene expression databases. Based on results from our preliminary models, we have submitted a step one proposal to NASA to search for radioprotective drugs to safeguard astronauts from radiation during spaceflight. An SBIR proposal will also be submitted to the NIH to propose drugs to protect workers in the nuclear energy industry and the military from the effects of radiation, and in a clinical setting, to increase the radiation sensitivity of tumor tissue for those patients receiving radiation therapy. As we all know, Predictive Oncology's two most valuable assets are the biobank of more than 150,000 tumor samples and a repository of drug response data, which are integral to our PEDAL drug discovery platform, both to evaluate and guide the design of experiments and models. Most of our current projects utilize PEDAL to direct drug screening in silico in order to minimize the time and material spent on physical laboratory experiments. The collaboration between Predictive Oncology and Cvergenx is driving expansion of those data sets, which may be leveraged in several important ways with respect to commercialization. First, to screen individuals for radiation sensitivity or resistance to improve the therapeutic effect of radiotherapy. Second, to screen for interactions between sensitive or resistant patient tumor samples and therapeutic compounds. And third, to identify, combine, or develop novel or repurposed radioprotective or radiosensitizing drugs. Separately but simultaneously, we have successfully developed a novel formulation for a protein drug candidate for an international pharmaceutical company that enabled that company to proceed with their toxicology studies. And in addition to existing contracts with biotech and biopharma companies, we are collaborating with FluGen on a next-generation vaccine related to respiratory disease, for which a phase IIB grant has already been submitted to the NIH. Most recently, we just returned from BIO-Europe, where we met with 40 different pharmaceutical companies over three days. Several of these companies have expressed interest in our formulation services and the purchase of our endotoxin products. In addition, three other companies expressed interest in purchasing our proprietary High Throughput Self-Interaction Chromatography platform, referred to as HSC, that enables rapid high-volume screening to determine the optimum solubility and stability conditions for new vaccines. These contracts point to the versatility of our technology to positively impact a broad spectrum of early drug discovery and development projects, and we look forward to more such announcements in the near future. For example, we continue to make progress on a novel method to express and stabilize GPCRs, G protein-coupled receptors, which is an important class of membrane proteins that represent an emerging market in cancer drug discovery. It is worth repeating that while we are clearly hyper-focused on securing high-value PEDAL drug discovery contracts, we do recognize that these engagements do take time. To support these efforts, we also have a very active biologics business, wherein formulation development and quality control testing are provided to our pharmaceutical development partners on a fee-for-service basis. This is relevant because protein therapeutics play a meaningful role in almost every field of medicine, from antibodies to enzymes and hormone treatments. The number and frequency of protein therapeutics brought to market has increased dramatically. But for these therapies to be effective, an optimal dose of the therapy must be properly circulated, delivered, and absorbed in the body. Not unlike the efficient predictive accuracy of the PEDAL platform for drug discovery, our biologics capabilities enable us to efficiently streamline and accelerate the formulation process, identify alternative and more viable formulations for commercial production and drug discovery applications. I point this out because this company is well-positioned to generate near-term formulations revenue to supplement building a pipeline of milestone-driven PEDAL contracts. Finally, last quarter, we announced the creation of a business advisory board and the appointment of two individuals with highly relevant, yet diverse expertise. Dr. Bernard A. Harris Jr., who brings with him a wealth of clinical, business, and operational healthcare experience, and finance veteran Andrew Einhorn, who has served as senior finance executive for a broad range of biopharmaceutical companies. As our momentum continues to accelerate, the business advisory board's insights, expertise, and perspectives will be invaluable in our efforts to deliver unique solutions to our drug development partners while creating lasting value for our shareholders. We are seeking many outstanding candidates who would add to the diversity of backgrounds and perspectives as we seek to round out our business advisory board. At this point, I would like to introduce our new Interim Chief Financial Officer, Josh Blacher. Josh joined us in August and served as our principal financial officer and principal accounting officer. Josh has served as CFO for several public and private life sciences companies. I'm pleased to have Josh on board, and he has already had a positive impact on helping some of our operating businesses focus more on top-line growth and profitability, introducing efficiencies in the finance and accounting department, and helping roll out a more robust investor relations program. At this point, I will turn the call over to Josh to review the financials. Josh? Thank you, Raymond. We ended the third quarter of 2023 with cash and cash equivalents of $11.9 million, as compared to $22.1 million as of December 31, 2022. In addition, we have 1.8 million outstanding warrants that represent potential source of capital in the future. We have no long-term debt, so our balance sheet is strong. As of September 30, 2023, stockholders' equity stood at $11.7 million, as compared to $21.8 million as of December 31, 2022. We recorded third quarter 2023 revenue of $715,000, as compared to $456,000 for the third quarter of 2022. Our gross margin in the third quarter of 2023 was 85%, as compared to 76% for the third quarter of 2022. Operating expenses were $3.8 million in the third quarter of 2023, down from $4.5 million in the third quarter of 2022. Net cash used in operating activities was $10.1 million for the nine months ended September 30, 2023, as compared to $9.1 million for the comparable period in 2022. Net cash used in investing activities was approximately $310,000 for the nine months ended September 30, 2023, as compared to $412,000 for the comparable period in 2022. That concludes our financial summary. You can find additional details in our 8-K containing our earnings press release, as well as our 10-Q, which is on file with the SEC and available on our website. With that, I'm going to turn the call now over to the operator for Q&A. As a reminder, Dr. Pamela Bush, our Chief Business Officer, is also available for this segment of the call. Thank you. We will now be conducting a question-and-answer session. If you would like to ask a question, please press star and then one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star and then two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please, while we poll for questions. Just once again, if you would like to ask a question, you're welcome to press star and then one. It seems that at this time we have no questions on the lines, and I would like to turn the floor back over to Raymond Vennare for closing comments. Irene, thank you very much. So everyone, that concludes our call for today. We hope that you take away from this call that the entire Predictive Oncology team is very excited about the growth trajectory that we are currently on. In the coming quarters, I would anticipate more collaborations and partnerships with some of the world's leading drug developers and research and academic institutions. And we are very excited to be at the forefront of AI and early drug discovery, playing an important role in the discovery of new oncology drugs, which we believe will not only benefit patients, but also create enduring value for our shareholders as well. Thank you again for your support, and I look forward to our next quarterly update in March. Have a good day.